An observational study in Cerebral Hemorrhage and Acute Lobar Haematoma, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.
Among the 24 studies in Cerebral Hemorrhage with a site in France, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 18th registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:
University Hospital, Tours · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18–65 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Tours · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is below the median of 300 across 181 observational studies indexed under Cerebral Hemorrhage.
Median enrollment 300 across the 13 interventional studies, 455 across the 11 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 24 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 1 study filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Hemorrhage with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06781034Centre Hospitalier Universitaire de NīmesDescriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies | 2026-12 |
| NCT06802588University Hospital, ToursOptimization of the Management of Non-Traumatic Intracerebral Hemorrhage (OPT-ICH) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Cerebral Hemorrhage with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.
Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.
An equivalent marker has also been described in gadolinium-enhanced MRI.
By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.
Patients with acute cerebral hematoma from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy; who underwent a follow-up cerebral CT scan in the event of worsening or for follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None, pure observational study
Other: None, pure observational study
None, pure observational study
Presence of spot sign on gadolinium MRI
Presence of spot sign on gadolinium MRI (Yes/No)
Time frame: baseline
Morphologic description of gadolinium MRI spot sign
morphological (shape, location within the hematoma) description of spot signs on brain MRI
Time frame: baseline
Quantitative description of gadolinium MRI spot sign
Quantitative (number and categorial) description of spot signs on brain MRI
Time frame: baseline
association of spot sign with hematoma expansion on follow-up CT
association of spot sign with hematoma expansion on follow-up CT(Yes/No)
Time frame: Baseline
Association with the underlaying pathology
Association with the underlaying pathology as identified by the authors (Yes/No)
Time frame: Baseline
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →